πŸ‡ΊπŸ‡Έ FDA
Patent

US 9326991

Nucleotide prodrug compounds and use

granted A61KA61K31/7056A61K45/06

Quick answer

US patent 9326991 (Nucleotide prodrug compounds and use) held by Ligand Pharmaceuticals Incorporated expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ligand Pharmaceuticals Incorporated
Grant date
Tue May 03 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K31/7056, A61K45/06, A61P, A61P31/12